Rusdeep S Mundae1, Linda M Zangwill2, Sami W Kabbara3, Naama Hammel4, Christopher Bowd4, Felipe A Medeiros4, Christopher A Girkin5, Jeffrey M Liebmann6, Robert N Weinreb4, Akram Belghith4. 1. Hamilton Glaucoma Center, Shiley Eye institute and Department of Ophthalmology, University of California, San Diego, California; Saint Louis University School of Medicine, St. Louis, Missouri. 2. Hamilton Glaucoma Center, Shiley Eye institute and Department of Ophthalmology, University of California, San Diego, California. Electronic address: lzangwill@ucsd.edu. 3. Hamilton Glaucoma Center, Shiley Eye institute and Department of Ophthalmology, University of California, San Diego, California; The University of Arizona College of Medicine - Phoenix, Phoenix, Arizona. 4. Hamilton Glaucoma Center, Shiley Eye institute and Department of Ophthalmology, University of California, San Diego, California. 5. School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 6. Harkness Eye Institute, Columbia University Medical Center, New York, New York.
Abstract
PURPOSE: To evaluate the rate of peripapillary choroidal thinning in glaucoma patients and healthy controls using spectral domain optical coherence tomography. DESIGN: Cohort study. METHODS: Participants from the multicenter African Descent and Glaucoma Evaluation Study and Diagnostic Innovations in Glaucoma Study were included. The San Diego Automated Segmentation Algorithm was used to automatically segment and measure peripapillary choroidal thickness (PCT) from circle scans centered on the optic nerve head. The rate of PCT thinning was calculated using mixed effects models. RESULTS: Two hundred ninety-seven eyes with a median follow-up of 2.6 years were included. At baseline, the global mean PCT was significantly thinner in glaucoma patients than healthy control subjects (141.7 ± 66.3 μm vs 155.7 ± 64.8 μm, respectively; P < .001). However, when age was included in the model, this difference was no longer significant (P = .38). Both healthy controls and glaucoma patients had a significant decrease in mean (95% confidence interval) PCT change over time (-2.18 [-2.97 to -1.40 μm/year] and -1.88 [-3.08 to -0.67 μm/year], respectively) and mean PCT percent change over time (-3.32% [-4.36 to -2.27 μm/year] and -2.85% [-4.64 to -0.99 μm/year], respectively). No significant difference was found between healthy control subjects and glaucoma patients in the mean rate of PCT change (P = .28) or PCT percentage change over time (P = .23). CONCLUSIONS: The rate of peripapillary choroidal thinning was not significantly different between healthy and glaucoma eyes during this relatively short follow-up period. Longer follow-up is needed to determine whether monitoring the rate of PCT change has a role in glaucoma management.
PURPOSE: To evaluate the rate of peripapillary choroidal thinning in glaucomapatients and healthy controls using spectral domain optical coherence tomography. DESIGN: Cohort study. METHODS:Participants from the multicenter African Descent and Glaucoma Evaluation Study and Diagnostic Innovations in Glaucoma Study were included. The San Diego Automated Segmentation Algorithm was used to automatically segment and measure peripapillary choroidal thickness (PCT) from circle scans centered on the optic nerve head. The rate of PCT thinning was calculated using mixed effects models. RESULTS: Two hundred ninety-seven eyes with a median follow-up of 2.6 years were included. At baseline, the global mean PCT was significantly thinner in glaucomapatients than healthy control subjects (141.7 ± 66.3 μm vs 155.7 ± 64.8 μm, respectively; P < .001). However, when age was included in the model, this difference was no longer significant (P = .38). Both healthy controls and glaucomapatients had a significant decrease in mean (95% confidence interval) PCT change over time (-2.18 [-2.97 to -1.40 μm/year] and -1.88 [-3.08 to -0.67 μm/year], respectively) and mean PCT percent change over time (-3.32% [-4.36 to -2.27 μm/year] and -2.85% [-4.64 to -0.99 μm/year], respectively). No significant difference was found between healthy control subjects and glaucomapatients in the mean rate of PCT change (P = .28) or PCT percentage change over time (P = .23). CONCLUSIONS: The rate of peripapillary choroidal thinning was not significantly different between healthy and glaucoma eyes during this relatively short follow-up period. Longer follow-up is needed to determine whether monitoring the rate of PCT change has a role in glaucoma management.
Authors: Takamitsu Fujiwara; Yutaka Imamura; Ron Margolis; Jason S Slakter; Richard F Spaide Journal: Am J Ophthalmol Date: 2009-07-09 Impact factor: 5.258
Authors: Jean-Claude Mwanza; Jessica T Hochberg; Michael R Banitt; William J Feuer; Donald L Budenz Journal: Invest Ophthalmol Vis Sci Date: 2011-05-18 Impact factor: 4.799
Authors: Hamid Hosseini; Naveed Nilforushan; Sasan Moghimi; Elena Bitrian; Jay Riddle; Gina Yoo Lee; Joseph Caprioli; Kouros Nouri-Mahdavi Journal: J Ophthalmic Vis Res Date: 2014-04
Authors: Brandon J Wong; Sasan Moghimi; Linda M Zangwill; Mark Christopher; Akram Belghith; Eren Ekici; Christopher Bowd; Massimo A Fazio; Christopher A Girkin; Robert N Weinreb Journal: Am J Ophthalmol Date: 2019-11-23 Impact factor: 5.258
Authors: Patricia Isabel C Manalastas; Akram Belghith; Robert N Weinreb; Jost B Jonas; Min Hee Suh; Adeleh Yarmohammadi; Felipe A Medeiros; Christopher A Girkin; Jeffrey M Liebmann; Linda M Zangwill Journal: Am J Ophthalmol Date: 2018-05-09 Impact factor: 5.258
Authors: Jasmin Rezapour; Christopher Bowd; Jade Dohleman; Akram Belghith; James A Proudfoot; Mark Christopher; Leslie Hyman; Jost B Jonas; Massimo A Fazio; Robert N Weinreb; Linda M Zangwill Journal: Sci Rep Date: 2021-04-23 Impact factor: 4.996
Authors: Christopher A Girkin; Akram Belghith; Christopher Bowd; Felipe A Medeiros; Robert N Weinreb; Jeffrey M Liebmann; James A Proudfoot; Linda M Zangwill; Massimo A Fazio Journal: Invest Ophthalmol Vis Sci Date: 2021-04-01 Impact factor: 4.925
Authors: Christopher A Girkin; Massimo A Fazio; Christopher Bowd; Felipe A Medeiros; Robert N Weinreb; Jeffrey M Liebmann; James Proudfoot; Linda M Zangwill; Akram Belghith Journal: Invest Ophthalmol Vis Sci Date: 2019-10-01 Impact factor: 4.799